| First Author | Tan S | Year | 2018 |
| Journal | Mol Med Rep | Volume | 18 |
| Issue | 2 | Pages | 1305-1310 |
| PubMed ID | 29901197 | Mgi Jnum | J:271953 |
| Mgi Id | MGI:6282748 | Doi | 10.3892/mmr.2018.9152 |
| Citation | Tan S, et al. (2018) CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells. Mol Med Rep 18(2):1305-1310 |
| abstractText | Chemokines have been demonstrated to serve an important role in a variety of diseases, particularly in tumor progression. There have been numerous studies that have reported that T cells serve major roles in tumor progression. However, the function of CXC motif chemokine ligand 9 (CXCL9) in prostate cancer remains unknown. The present study aimed to investigate the role of CXCL9 in prostate cancer. A prostate cancer mouse model was generated by treating C57/BL6 and B6.CgSelplgtm1Fur/J mice with 3,2'dimethyl 4aminobiphenyl (DMAB). Hematoxylin and eosin staining detected the histopathological alterations of mouse prostate tissues. Immunohistochemistry (IHC) staining determined cell proliferation of the mice. Flow cytometry was used to detect the alterations of T cells in C57+DMAB or CXCL9+DMAB mice. Immunofluorescence revealed that there was positive expression of interleukin6 (IL6) and transforming growth factor (TGF)beta in the mouse tissues. The survival rates of C57+DMAB and CXCL9+DMAB mice was analyzed. The association of CXCL9 expression and clinical stages was also evaluated. Results revealed that prostate cancer pathology and cell proliferation in CXCL9+DMAB mice were significantly greater compared with the C57+DMAB mice. Compared with C57+DMAB mice, the number of T cells in peripheral blood and spleen of CXCL9+DMAB mice was significantly reduced. IHC demonstrated that the expression of IL6 and TGFbeta was significantly downregulated in the CXCL9+DMAB mice. The survival rate of CXCL9+DMAB mice was significantly decreased compared with the C57+DMAB mice. In addition, reverse transcriptionquantitative polymerase chain reaction analysis demonstrated that CXCL9 mRNA expression in clinical samples was positively associated with clinical pathological stages of prostate cancer. In conclusion, CXCL9 may promote prostate cancer progression via inhibition of cytokines from T cells. |
